Enrolling

A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

J2P-MC-LXBD -

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP).

Enter your city or zip code to find the nearest site

See if You May Qualify

Answer a few questions to see if you meet key criteria for this study.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Diabetic Peripheral Neuropathy
What the trial is testing?
LY3556050
Could I receive a Placebo?
Yes
Enrollment Goal
410
Trial Dates
Oct 5, 2023 - Jan 2025
How long will I be in the trial?
The study will last about 24 weeks and may include up to 15 visits.
Trial Phase
II

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Are at least 18 years old or older at time of ICF signature

  • Have Type 1 Diabetes or Type 2 Diabetes for at least 6 months prior to screening

  • Have a stable glycemic control on stable diabetes treatment regimen for at least 90 days prior to day 1 with a hemoglobin A1c (HbA1c) ≤10 for T1D and HbA1c ≤11 for participants with T2D at time of screening

  • Are willing to discontinue all medications taken for chronic pain conditions

  • Are willing to abide by reproductive and contraceptive requirements

Participants Must Not:

  • Have history of painful neuropathies other than DPNP

  • Have symptomatic peripheral vascular disease

  • Have uncontrolled diabetes

  • Have a surgery planned

  • Have had cancer in past 2 years

Lilly Trial Alerts

Sign up to receive updates about new trials and find out when a clinical trial site near you starts enrolling.

Clinical Trial Resources